Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Cipla_USA_Inc.
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:CEO |
gptkb:Blake_Wise
|
| gptkbp:FDAApproved |
plazomicin (2018)
|
| gptkbp:filedForBankruptcy |
2019
|
| gptkbp:focusesOn |
antibiotic development
|
| gptkbp:founded |
2002
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Achaogen
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:plazomicin
|
| gptkbp:numberOfEmployees |
~200 (at peak)
|
| gptkbp:plazomicinBrandName |
gptkb:Zemdri
|
| gptkbp:primaryTherapeuticArea |
infectious diseases
|
| gptkbp:stockSymbol |
gptkb:AKAO
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.achaogen.com
|
| gptkbp:bfsParent |
gptkb:Nathaniel_David
|
| gptkbp:bfsLayer |
6
|